Drug Patents owned by Amryt

1. Drug name - JUXTAPID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10555938 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects Mar, 2025

(2 years from now)

US8618135 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects Mar, 2025

(2 years from now)

US9265758 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects Mar, 2025

(2 years from now)

US9364470 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects Mar, 2025

(2 years from now)

US9433617 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects Mar, 2025

(2 years from now)

US9861622 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects Mar, 2025

(2 years from now)

US10016404 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects Mar, 2025

(2 years from now)

US7932268 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects Aug, 2027

(4 years from now)

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription
EQ 20MG BASE CAPSULE;ORAL Prescription
EQ 30MG BASE CAPSULE;ORAL Prescription
EQ 40MG BASE CAPSULE;ORAL Discontinued
EQ 60MG BASE CAPSULE;ORAL Discontinued

2. Drug name - MYCAPSSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329198 AMRYT Pharmaceutical compositions and related methods of delivery Sep, 2029

(6 years from now)

US8535695 AMRYT Pharmaceutical compositions and related methods of delivery Sep, 2029

(6 years from now)

US9566246 AMRYT Pharmaceutical compositions and related methods of delivery Sep, 2029

(6 years from now)

US9265812 AMRYT Pharmaceutical compositions and related methods of delivery Sep, 2029

(6 years from now)

US10238709 AMRYT Method of treating diseases Feb, 2036

(13 years from now)

US10695397 AMRYT Method of treating diseases Feb, 2036

(13 years from now)

US11052126 AMRYT Method of treating diseases Feb, 2036

(13 years from now)

US11141457 AMRYT Oral octreotide therapy and contraceptive methods Dec, 2040

(18 years from now)

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.